Effect of prostaglandin F2 alpha on uterine or ovarian secretion of prostaglandins E and F2 alpha in vivo in 90-100 day hysterectomized, intact or ovariectomized pregnant ewes.
Vehicle or 8 or 16 mg of PGF2 alpha per 58 kg body weight was given intramuscularly to intact, hysterectomized or ovariectomized 90-100 day pregnant ewes in three separate experiments. Both doses of PGF2 alpha increased PGF2 alpha in ovarian venous plasma compared with controls at 72 hr post treatment in intact (P < or = 0.05) but did not in hysterectomized (P > or = 0.05) 90-100 day pregnant ewes. Concentrations of PGE in ovarian venous blood of intact ewes did not differ (P > or = 0.05) between treatment groups and were equivalent to concentrations of PGE determined in uterine venous plasma. PGE was decreased in ovarian venous plasma by PGF2 alpha in hysterectomized ewes (P < or = 0.07). PGE in uterine venous plasma averaged 6 ng/ml over the 72-hr treatment period in intact and ovariectomized 90-100 day pregnant ewes and was 12 fold greater (P < or = 0.05) than PGF2 alpha which averaged 500 pg/ml in uterine venous plasma. Both PGF2 alpha and PGE increased (P < or = 0.05) by 64 hr in uterine venous plasma of the 8 mg PGF2 alpha-treated intact pregnant ewes. A significant quadratic increase (P < or = 0.05) was observed for PGF2 alpha and PGE in the vehicle and both PGF2 alpha treatment groups of intact ewes at the end of the 72-hr sampling period. It is concluded that the uterus and ovaries secrete significant quantities of PGF but little PGF2 alpha during midgestation. In addition, PGF2 alpha increased uterine secretion of PGE in vivo. PGE may be a placental stimulator of ovine placental secretion of progesterone or PGE may protect placental steroidogenesis from actions of PGF2 alpha.
Weems
Y S
YS
Department of Animal Sciences, University of Hawaii, Honolulu 96822.
Vincent
D L
DL
Nusser
K D
KD
Tanaka
Y
Y
Miller-Patrick
K
K
Ledgerwood
K S
KS
Weems
C W
CW
D000704:Analysis of Variance; D000818:Animals; D015237:Dinoprost / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D007044:Hysterectomy; D007700:Kinetics; D010052:Ovariectomy; D010053:Ovary / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000502:physiology*; D011458:Prostaglandins E / Q000097:blood / Q000378:metabolism*; D012039:Regional Blood Flow; D012756:Sheep; D013997:Time Factors; D014599:Uterus / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism*
D011458:Prostaglandins E; D015237:Dinoprost